Financial Performance - The company achieved operating revenue of ¥1,595,372,919.28, a year-on-year increase of 10.57%[4] - Net profit attributable to shareholders decreased by 11.08% to ¥651,175,616.96[4] - Basic earnings per share were ¥5.66, down 11.01% compared to the previous year[4] - Shareholders' equity attributable to the company rose by 23.39% to ¥1,894,316,349.28[5] Assets and Growth - Total assets increased by 25.62% to ¥2,582,826,141.71[5] Product Innovation - The company launched the world's first injectable recombinant type III humanized collagen gel, showcasing original innovative technology[8] - The company is focusing on original innovation and increasing investment in a series of innovative products, leading to higher R&D expenses[8] Business Segments - The functional skincare business grew rapidly, but its gross margin is lower than that of medical device products, affecting overall gross margin[7] Marketing and Expenses - The company increased brand promotion and marketing expenses to strengthen brand awareness and new product launches[7] Regulatory Impact - The net profit decline was primarily due to a VAT rate increase from 3% to 13% on medical device products starting January 1, 2025[6]
锦波生物(920982) - 2025 Q4 - 年度业绩